Viking Therapeutics VKTX Interest Income (Expense), Nonoperating
Interest Income (Expense), Nonoperating at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's interest income (expense), nonoperating?
- Viking Therapeutics (VKTX) reported interest income (expense), nonoperating of $5.8M in Q1 2026.
- How has Viking Therapeutics's interest income (expense), nonoperating changed year-over-year?
- Viking Therapeutics's interest income (expense), nonoperating decreased by 41.2% year-over-year, from $9.86M to $5.8M.
- What is the long-term trend for Viking Therapeutics's interest income (expense), nonoperating?
- Over 4 years (2021 to 2025), Viking Therapeutics's interest income (expense), nonoperating has grown at a 163.0% compound annual growth rate (CAGR), from $704K to $33.7M.